NEW YORK (GenomeWeb News) – Becton Dickinson's BD Diagnostics segment today said that its BD Max Cdiff Assay has been cleared by the US Food and Drug Administration for marketing in the US.

The assay runs on the BD Max System and detects the toxin B gene, which has been implicated as a cause of disease in patients suspected of having Clostridium difficile. The assay was CE-marked in March 2012.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.